[ET Net News Agency, 17 September 2021] Citi lowered its target price for Lee's Pharm
(00950) to HK$6.5 from HK$6.83 and maintained its "buy" rating.
The research house said downside risks that could cause the stock to fail to meet the
target price include further tender price cut; slower-than-expected new product launches;
sales under agency model might face two-invoice policy impact in some provinces. (RC)